ClinicalTrials.Veeva

Menu
East Florida Eye Institute | Stuart logo

East Florida Eye Institute | Stuart

Research site
About
East Florida Eye Institute is at the forefront of ophthalmic research, contributing to the development of innovative treatments for eye conditions. We are excited to offer our patients the opportunity to participate in groundbreaking studies.

Site insights

Top conditions

Top treatments

APL-2
Abicipar Pegol
RVL-1201
Bimatoprost
Aflibercept
Bevacizumab
Squalamine Lactate
ANX007
PVP
Timolol Maleate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Joe Boban

Verified by this site

Active trials

10 of 32 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901
Locations recently updated

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham
Locations recently updated

This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Enrolling
Geographic Atrophy
Drug: BI 1584862
Drug: Placebo-matching BI 1584862

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling
Open-angle Glaucoma
Ocular Hypertension
Other: Sham Administration
Drug: AGN-193408 SR

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).

Enrolling
Diabetic Macular Edema
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

Trial sponsors

Allergan logo
A
Boehringer Ingelheim logo
R
S
Shire logo
4
AbbVie logo
Aerie Pharmaceuticals logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems